Antidiphtheria

Основна информация

  • Търговско наименование:
  • Antidiphtheria serum Bul Bio, sol. inj. amp. 5000 IU x 10
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Antidiphtheria serum Bul Bio, sol. inj. amp. 5000 IU x 10
    България
  • Език:
  • български

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20020930
  • Дата Оторизация:
  • 25-04-2013
  • Последна актуализация:
  • 01-06-2018

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Opinion/decision on a Paediatric investigation plan (PIP): diphtheria toxin interleukin-3 Fusion Protein, decision type: , therapeutic area: , PIP number: P/0326/2018

Europe - EMA - European Medicines Agency

19-12-2018

Hexacima (Sanofi Pasteur)

Hexacima (Sanofi Pasteur)

Hexacima (Active substance: Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)) - Centralised - Yearly update - Commission Decision (2018)9062 of Wed, 19 Dec 2018

Europe -DG Health and Food Safety

19-12-2018

Hexyon (Sanofi Pasteur)

Hexyon (Sanofi Pasteur)

Hexyon (Active substance: diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)) - Centralised - Yearly update - Commission Decision (2018)9061 of Wed, 19 Dec 2018

Europe -DG Health and Food Safety

29-11-2018


Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein, Treatment of blastic plasmacytoid dendritic cell neoplasm, 11/11/2015, Positive

Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein, Treatment of blastic plasmacytoid dendritic cell neoplasm, 11/11/2015, Positive

Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein, Treatment of blastic plasmacytoid dendritic cell neoplasm, 11/11/2015, Positive

Europe - EMA - European Medicines Agency

21-11-2018

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (Active substance: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein) - Transfer of orphan designation - Commission Decision (2018)7816 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/15/T/02

Europe -DG Health and Food Safety